Torrent Pharmaceuticals Marks Global Expansion With Net 20% Year-over-Year Profit: Statement released in Q1 FY26 Report
PharmaGenDRx News Bureau – 30th July,2025
10:00 AM IST
Torrent Pharmaceuticals Limited has announced a strong financial result for Q1 FY26. The company announced a total revenue of ₹3,178 crore, embarking on an 11% year on year growth. Net profit advanced by 20% to ₹548 crore. Operating EBITDA climbed 14% year-on-year reaching ₹1,032 crore, with margins improving to 32.5%, while the adjusted margin excluding acquisition costs stood at 32.9%.
There was an increase in the revenue from the Indian market, a whooping 11% or ₹1,811 crore, in monetary terms. The company’s chronic therapy segment has seen significant success. Torrent’s 21 brands are among the top 500 of IPM, and 14 brands have sales of more than ₹100 crore.
International markets have also performed well. Revenue in Brazil grew by 11% (16% in
local currency), revenue in the US by 19% (16% in local currency), and in Germany by 9%, despite some supply chain issues.
The company had allocated a 16% higher investment, summing up to ₹157 crore in the Research & Development sector. Torrent operates currently across 50 countries and owns 8 manufacturing units 5 of which are USFDA approved. The company is now ranked 7th in the Indian pharma market and holds the leadership of several therapeutic areas.
By Arghyadeep Biswas.
